Longitudinal tracking of FTLD: toward developing clinical trial methodology.

Area of Science:

• Neuroscience
• Clinical Neurology
• Medical Research Methodology

Background:

• Frontotemporal lobar degenerations (FTLD) are a group of progressive neurodegenerative disorders.
• Effective clinical trials are crucial for developing new treatments for FTLD.
• Several challenges impede the design and execution of robust FTLD clinical trials.

Purpose of the Study:

• To outline key considerations for designing clinical trials targeting frontotemporal lobar degenerations.
• To review current diagnostic criteria and measurement instruments for FTLD research.
• To explore the potential role of biomarkers in FTLD clinical trial design.

Main Methods:

• Review of diagnostic criteria for frontotemporal lobar degenerations.
• Evaluation of instruments for longitudinal assessment in FTLD studies.
• Discussion of study duration and biomarker utilization in clinical trials.
• Description of a multicenter trial investigating diagnostic and measurement aspects of FTLD.

Main Results:

• Identified critical conceptual, methodologic, and diagnostic issues in FTLD clinical trial design.
• Highlighted the importance of standardized diagnostic criteria and validated longitudinal measures.
• Emphasized the potential utility of biomarkers for enhancing FTLD trial efficiency and interpretation.
• Initiated a multicenter trial to empirically address specific FTLD research design challenges.

Conclusions:

• Resolving diagnostic and methodological challenges is essential for advancing FTLD clinical trials.
• Standardized approaches to diagnosis and longitudinal measurement are needed.
• Biomarkers offer promising avenues for improving FTLD clinical trial design and outcomes.
• Further research, including multicenter trials, is vital for optimizing FTLD therapeutic development.